

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
S531
(GAF), Structured Clinical Interview (SCID 1-2), Level of Expressed
Emotion Scale (LEE), Paykel scale, State and Trait Anxiety Inven-
tory (STAY 1-2), State-Trait Anger Expression Inventory (STAXY),
Barratt Impulsiveness Scale (BIS-11).
Results
Levels of anxiety (both state and trait) are higher in the
ED group than in SCHZ. As far as the STAXY is concerned, SCHZ
patients score higher than ED ones on control over anger, while
general index of anger expressionwas higher in ED patients. We did
not find significant differences in EE between two groups, except
for the patient’s emotional response of the patient to the disease,
which was greater among SCHZ. Both SCHZ and ED patients scored
higher on the LEE, Paykel and STAY than their caregivers.
Conclusions
SCHZ and ED patients show different patterns of
anxiety and anger, but similar profile as far as EE is concerned.
Implications for treatment will be discussed.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.1551EV567
Multifactorial ethiopathogenic in
eating disorders
E. Garcia
1 ,∗
, M. Leon
2, F. Polo
21
Ciudad Real, Spain
2
Hospital General de Ciudad Real, UTCA, Ciudad Real, Spain
∗
Corresponding author.
Eating Disorders is a heterogeneous group of syndromes which
includes many factors in their develop. The three main syndromes,
AN, BN and EDNOS has been defined in last DSM as indepen-
dent entities. However is well known that a group of patients may
change its presentation along time, so also been at first diagnosed
of AN, lately will fulfil criteria for BN or EDNOS.
In the other hand, if we compare two patients with the same syn-
drome, as BN, or AN
. . .
We may easily find big differences in personality, stressors
. . .
and
in some cases the only common factor is the clinical presentation.
Behind all of this is the fact that syndromic classification drives to
empiric treatments that are far the most validated.
But although there is a well known evolution in this disorders, with
a not so bad income as one could think initially (in some cases one
third could recover without treatment), whatmaywe dowith those
patients that are resistant for empiric treatments?
And it is our opinion that a deeper knowledge of all the factors that
contribute to the syndrome or its presentation, as well as those
related to treatments results, should be taken into account.
We have reviewed all knowledge about these issues and we have
completed it with our clinical practise using a 50 patients data base,
here we will show our results, that are basically that even the same
factors interact in different ways in each patient, so it is not just the
ingredients but the recipe.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.1552EV568
Atypical antipsychotics use in eating
disorders. Review
J.M. Hernández Sánchez
1 ,∗
, M .F. Molina López
2 ,M.C. Cancino Botello
2, M.Á. Canseco Navarro
2, D. Pe˜na Serrano
21
Valencia, Spain
2
Hospital General de Valencia, Psychiatry, Valencia, Spain
∗
Corresponding author.
Introduction
Eating disorders often have serious medical com-
plications, including the highest mortality rates of any psychiatric
disorder. The search for an optimal therapeutic strategy during the
last decades has been difficult and it has included antidepressants,
antipsychotics, anticonvulsants, benzodiazepines and mood sta-
bilisers.
Objectives
To review the medical literature related to the treat-
ment of eating disorders with atypical antipsychotics.
Methods
Medline search and ulterior review of the related liter-
ature. Keywords: “eating disorders”; “anorexia nervosa”; “bulimia
nervosa”; “binge eating disorder”; “antypsychotic agents”.
Results
To the date, most of the studies have been with olan-
zapine. Olanzapine has shown effects, not only on weight gain,
but also on management of other psychological features such as
obsessive-compulsive symptoms, depression, aggression, persis-
tence and interpersonal distrust. However, most of these studies
have been compared to placebo, and binge-eating behaviour has
also been described when using olanzapine (not with aripiprazole
or ziprasidone). Recently, Marzola et al, when comparing olanza-
pine + SSRIs versus aripiprazol + SSRIs, described that aripiprazole
(compared to olanzapine) is significantlymore effective in reducing
purging episodes, eating preoccupations and rituals.
Conclusions
So far, aripiprazol and olanzapine have been proved
to be the most effective atypical antypsichotics in eating disor-
ders, especially in anorexia nervosa. However, most of studies were
placebo-controlled and in quite small samples. Further investiga-
tion is needed.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
Further readings
Marzola E et al. Atypical antipsychotics as augmentation therapy in
anorexia nervosa. Plos One 2015;10(4):e0125569.
Brewerton TD. Antipsychotic agents in the treatment of anorexia
nervosa: neuropsychopharmacologic rationale and evidence from
controlled trials. Curr Pschiatry Rep 2012;14(4):398–405.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.1553EV569
Patients with anorexia nervosa:
Outcome inpatient care
J. Jerónimo
∗
, J. Santos , L. Castro Nunes , S. Neves , F. Sequeira ,
A. Neves
Santa Maria’s Hospital, CHLN, Psychiatry and Mental Health
Department, Lisboa, Portugal
∗
Corresponding author.
Introduction
Anorexia nervosa (AN) is characterized by self-
induced starvation coupled with fear of gaining weight and a
distorted body image. Its treatment is complex and challenging,
and sometimes hospitalization is needed.
Santa Maria Hospital’s Eating Disorders Unit (SMH-EDU) is a mul-
tidisciplinary team, formed in 1989, that provides both outpatient
and inpatient treatment.
Objective
To present and discuss SMH-EDU’s AN treatment and
its results.
Methods
Revision and statistical analysis of all hospitalized AN’
patients’ clinical files, from 1 January 2014 to 31 December 2014.
Treatment outcome was assessed by BMI variation.
Results
A total of 45 admissions (41 patients) were analysed:
75.65% had AN restricting type and 24.45% had AN purging type.
All patient were females, with median age of 27 years old (range
12–57 years). Average admission BMI was 14.51 kg/m
2
(ranging
from11.19 to 17.77 kg/m
2
). The mean lengths of stay were 39 days.
Thirty-six percent of the patients had at least one previous hos-
pitalization. Only 2 patients were readmitted at SMH-EDU: triple
readmissions. The mean time between the beginning of the disor-
der and the admission was 111months (ranging 2 to 408months).
Average discharged BMI was 16.32 kg/m
2
(ranging from 13.24 to
19.11 kg/m
2
).
Conclusion
Inpatient treatment for AN at SMH-EDU is consid-
ered only for those patients whose disorder has not improved with
appropriate outpatient treatment. Therefore, most inpatients at